Acadia Pharmaceuticals is showcasing Nuplazid at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.
Nuplazid is Acadia's commercial anchor and the only FDA-approved treatment specifically for PDP. At APA, they'll target psychiatrists who co-manage psychosis in Parkinson's patients alongside neurologists. The unique non-dopaminergic mechanism (doesn't worsen motor symptoms) is the key message for this audience.
Ask about: PDP diagnosis rates in psychiatric vs. neurological settings; real-world utilization data; how psychiatrists can identify PDP in their practices; ACP-204 (next-gen 5-HT2A for Alzheimer's psychosis) as the pipeline story — Phase 2 readout Aug-Oct 2026 is imminent and extends the same mechanism into a much larger market.
VoiceVitals objectively assesses hallucination/delusion severity through speech pattern analysis — critical for PDP where patients are seen infrequently by psychiatrists and clinician-rated scales are administered sporadically. ePRO+ supports caregiver-reported outcomes in a population with limited self-report capacity.
Position as continuous monitoring infrastructure between the neurologist and psychiatrist touchpoints.
Set up a follow-up with Acadia Pharmaceuticals's team and Videra Health.
Email Ryan Roberts →